RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention

From Awareness to Action: Transforming Proton Pump Inhibitor Use in Ras Al Khaimah Through Education and Intervention: the RAK -PRIDE Study

The goal of this study is to determine if a pharmacist-led educational intervention can reduce the inappropriate use of proton pump inhibitors (PPIs) among adult patients (≥18 years) with potentially inappropriate PPI prescriptions in Ras Al Khaimah.

The main questions it aims to answer are:

• Can a pharmacist-led education program reduce unnecessary PPI use?
• Does the intervention improve patients' quality of life and reduce healthcare costs? Researchers will compare the intervention group (receiving pharmacist-led education and materials) to the usual care group to see if the intervention reduces PPI use and improves patient outcomes.

Participants will:

• Receive educational materials from pharmacists, including a patient educational brochure, PPI patient decision aid, PPI deprescribing pamphlet, and PPI patient action plan.
• Physicians involved will also receive a pharmaceutical intervention, which includes a physician educational brochure, PPI evidence-based deprescribing guideline, PPI deprescribing algorithm, and whiteboard videos on PPI deprescribing.
• Patients will be followed up for 6 months to monitor changes in PPI use, symptoms, and quality of life.

The RAK-PRIDE Study aims to evaluate the impact of a pharmacist-led educational intervention on the inappropriate use of proton pump inhibitors (PPIs) among adult patients in Ras Al Khaimah. This intervention will focus on both patient education and physician guidance, promoting evidence-based deprescribing practices for PPIs.

Inclusion Criteria:

Physicians will be eligible to participate if:

• They are prescribing PPIs in outpatient department of the study sites
• They have patients with potentially inappropriate PPI prescriptions

Patients will be eligible to participate if:

• They are ≥18 years
• They are presenting to out-patient departments of the study sites
• They have prescriptions of potentially inappropriate PPIs
• Their treating physicians are included in the study

Exclusion Criteria:

Physicians will be excluded if:

• They are involved in any other prescribing trial

Patients will be excluded if:

• They are unable to give informed consent, as judged by their physicians
• They have definitive indications for PPI use